Surufatinib plus chemotherapy for advanced pancreatic cancer
Treatments studied
Part of Cancer clinical trials.
This Phase 2 study tests whether adding surufatinib to first-line treatment (either AG or a similar AG-based regimen) can improve outcomes for people with locally advanced or metastatic pancreatic cancer. You may be considered if your cancer cannot be removed by surgery and you’ve already had a short course of similar treatment with a response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have unresectable locally advanced or metastatic pancreatic cancer confirmed by biopsy or fluid test
- You are 18–75 years old and can be male or female
- Your general health score (ECOG) is 0–1, and you’re expected to live at least 12 weeks
- You had 2 cycles of an AG-type first-line treatment, and the results were complete response, partial response, or stable disease (with a specific rule for “increased after 2 cycles”)
- Your scans show at least one measurable tumor spot that is large enough to track (10 mm on MRI/CT or at least 20 mm on standard CT)
- Your blood, liver, kidney, and heart tests are within safe ranges, and you can use effective birth control during the study and for 6 months after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three medicines to see if they can slow down or shrink pancreatic cancer that has not responded to previous treatments or has come back. It might help if you are generally healthy and your cancer is advanced.
This trial tests a combination of four drugs given before surgery to shrink pancreatic tumors that are borderline resectable or high-risk. The goal is to make surgery more effective and improve outcomes.
This trial tests the drug surufatinib in people with advanced neuroendocrine tumors. It is a real-world study, meaning it looks at how the drug works in everyday practice, and may help control tumor growth.
This trial tests if adding surufatinib to standard chemotherapy before surgery can help people with a certain type of pancreatic cancer. The goal is to see if the combination shrinks the tumor more than chemotherapy alone.
This trial studies whether a combination of surufatinib and immunotherapy (camrelizumab, plus an “AS” medicine) can slow or shrink advanced pancreatic cancer that has spread. It is for people starting treatment for advanced disease for the first time and may help those who have measurable tumors and meet safety test limits.
This trial tests a new combination of three drugs for a type of pancreatic cancer that cannot be removed by surgery but has not spread to other parts of the body. The goal is to see if this combination can shrink or slow the cancer better than the current standard therapy.
Hear when a new Pancreatic Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.